Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of YH12852 After Oral Administration in Healthy Male Subjects
- Registration Number
- NCT01870674
- Lead Sponsor
- Yuhan Corporation
- Brief Summary
Study to evaluate the safety/tolerability and pharmacokinetics/pharmacodynamics(PK/PD)of YH12852 after oral administration in healthy subjects
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 127
Inclusion Criteria
- healthy male/female aged 19 to 45 with body mass index(BMI) between 18 and 25kg/m2
- Subject who has no congenital, chronic disease and disease symptoms in medical examination result
- Subject who is judged to be eligible by principal investigator or sub-investigator according to various reasons including their abnormal test results(clinical laboratory test, 12-lead ECG etc)
- Subjects who has signed a written informed consent voluntarily,prior to any procedure, using a form that is approved by the local Institutional Review Board after detail explanation of the purpose, contents, and characteristic of the drug
Exclusion Criteria
- Subject who has history or presence of clinically significant diseases in liver, kidney, gastrointestinal tract, nervous system, respiratory system, endocrine system, blood tumor, cardiovascular, urinary system, and mental disorder
- Subject who is hypersensitive to components contained in YH12852 or prucalopride or aspirin/antibiotics like drugs
- Medical history of gastrointestinal disease or acid restraining surgery, gastric/ esophagus surgery(excluding appendectomy, hernia surgery)
- Clinically significant abnormal values in diagnostic check within 28 days before the treatment(>1.25 fold of normal upper limit in the levels of AST or ALT, >1.5 fold of normal upper limit in the levels of Total bilirubin, < 80ml/min of Cockcroft-Gault used creatinine clearance
- Subject has over QTc interval of 550 ms or PR interval of 210 ms or QRS interval of 120 ms or QT interval of 500 ms on baseline 12-lead ECG, as determined by the Investigator
- Subject who had taken usual dose of any prescription drugs within 14 days before the treatment or who had used usual dose of OTC drugs within 7 days before the treatment
- Subject who participated in another clinical trail within 2 months before enrolling in this study
- subject who donated whole blood within 2 months or component blood within 1 month before the treatment
- Medically unacceptable contraception used during the clinical trial
- Subject who drank over 30g/day or were detected alcohol positive on test
- Subject who stopped smoking within 3 months before the treatment or weren't able to stop smoking during the hospitalization
- Subject who had a beverage containing caffeine during the hospitalization
- Subjects with clinically significant observations considered as unsuitable based on medical judgment by investigators
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo Placebo \<each cohort\> Matching Placebo YH12852 YH12852 \<SAD cohort\> * Experimental: YH12852 1mg/single dose, qd * Experimental: YH12852 3mg/single dose, qd * Experimental: YH12852 10mg/single dose, qd \<FSD cohort\> * Experimental: YH12852 0.5mg/single dose, qd * Experimental: YH12852 1mg/single dose, qd * Experimental: YH12852 2mg/single dose, qd * Experimental: YH12852 3mg/single dose, qd \<MAD cohort\> * Experimental: YH12852 0.5mg/repeat dose, qd * Experimental: YH12852 1mg/repeat dose, qd * Experimental: YH12852 2mg/repeat dose, qd * Experimental: YH12852 3mg/repeat dose, qd * Each dosing group(except MAD cohort 0.5mg which has single treatment arm taking YH12852 only) contains 12 subjects. 12 subjects are administered YH12852 or placebo/active comparators.(YH12852:placebo:active=8:2:2) Prucalopride Prucalopride \<each cohort\> Prucalopride succinate 1.321mg
- Primary Outcome Measures
Name Time Method the number of adverse events, seriousness of adverse event D1~Post study visit significant changes in vital sign D1~Post study visit significant physical exam D1~Post study visit significant changes in 12-lead electrocardiography D1~Post study visit significant changes in laboratory test D1~Post study visit
- Secondary Outcome Measures
Name Time Method AUC 0~48 hrs(SAD,FSD cohorts), 0~24 hrs/D5,6 0hr/D7 0~48hrs(MAD cohort) BSFS D1~7(SAD, FSD cohorts), D1~14(MAD cohort) pharmacodynamics
Cmax 0~48 hrs(SAD,FSD cohorts), 0~24 hrs/D5,6 0hr/D7 0~48hrs(MAD cohort) Ae 0~48 hrs(SAD cohort), 0~24 hrs/D7 0~48hrs(MAD cohort) Frequency of defecation D1~7(SAD, FSD cohorts), D1~14(MAD cohort) pharmacodynamics
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular targets of YH12852 in modulating pharmacodynamic effects in healthy subjects?
How does YH12852 compare to prucalopride in terms of efficacy and safety profiles for gastrointestinal motility disorders?
What biomarkers are associated with response prediction to YH12852 in preclinical or clinical studies?
What adverse events were observed in NCT01870674 and how were they managed in the phase 1 trial?
What other 5-HT4 receptor agonists are being developed by Yuhan Corporation for gastrointestinal indications?
Trial Locations
- Locations (1)
Inje Busan Paik hospital
🇰🇷Busan, Korea, Republic of
Inje Busan Paik hospital🇰🇷Busan, Korea, Republic of